Get the Stockscreener App
14.59
1.08%
-0.16
After Hours:
14.55
-0.04
-0.27%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $14.59, with a volume of 14.34M.
It is down -1.08% in the last 24 hours and up +9.21% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$14.75
Open:
$14.75
24h Volume:
14.34M
Relative Volume:
1.41
Market Cap:
$16.99B
Revenue:
$14.29B
Net Income/Loss:
$-3.51B
P/E Ratio:
-4.9286
EPS:
-2.9603
Net Cash Flow:
$1.85B
1W Performance:
-0.61%
1M Performance:
+9.21%
6M Performance:
+40.97%
1Y Performance:
+81.69%
1-Day Range:
$14.42
$14.82
1-Week Range:
$14.36
$15.21
52-Week Range:
$7.935
$16.47
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.59 | 16.99B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
16.63 | 52.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.87 | 49.15B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.58 | 42.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
567.16 | 24.86B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Inc. stock rises Friday, outperforms market - MSN
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Discipline and Rules-Based Execution in VTRS Response - Stock Traders Daily
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
FDA Issues Nationwide Recall of ‘Extended Release’ Xanax for Anxiety - Healthline
Taking Xanax XR? FDA Recalls Batch Over Effectiveness Concerns - AOL.com
Viatris' Q1 2026 Earnings: What to Expect - Barchart
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Viatris Inc. (VTRS) Stock Analysis: Navigating Challenges With A 7.10% Potential Upside - DirectorsTalk Interviews
Transdermal Skin Patches Market 2026- 2033 Overview: Share, - openPR.com
FDA Lists Xanax Recall. Here’s What You Need To Know - Forbes
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Is Viatris Inc (VTRS) Overvalued After 4.7% Rally? GF Value Says - GuruFocus
Xanax recalled nationwide due to potential issue with quality, efficacy - The National News Desk
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Popular anxiety medication recalled nationwide after FDA warning - NewsNation
Xanax XR recalled after discovery that tablets may fail to release medication properly - Fox Business
Viatris (VTRS) CCO nets 107,135 shares after RSU and DEU vesting - Stock Titan
Why the Xanax recall may not impact your prescription - The Hill
Popular Prescription Medication Xanax Is Being Recalled Nationwide - AOL.com
Xanax from West Virginia-based company recalled nationwide. What you need to know - Los Angeles Times
Xanax bottles recalled nationwide over dissolution issues - WCVB
Popular anxiety Xanax drug recalled nationwide: How to check if your prescription is included - nypost.com
Xanax, popular anxiety medication, recalled: What to know - FOX 13 Tampa Bay
Popular anxiety drug Xanax recalled nationwide: What to know - NBC 5 Chicago
Bottles of Xanax, a popular anxiety drug, recalled nationwide. Here’s why - KFOR.com
Popular anxiety prescription recalled nationwide - WJHL
Bottles of Xanax recalled nationwide. Here’s why - CBS 42
Viatris Ophthalmology Data At ASCRS Puts Valuation And Dividend In Focus - Sahm
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 - Lelezard
FDA Recalls and Warnings: Potentially Contaminated Cough Drops and Eye Drops, Subpotent Thyroid Medications & More - MedShadow Foundation
Behavioral Patterns of VTRS and Institutional Flows - Stock Traders Daily
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
What to watch May 7: Viatris posts Q1 results, holds webcast - Stock Titan
Viatris Announces Multiple Data Presentations at ASCRS Annual Meeting - National Today
Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com
Xanax Has Been Recalled Nationwide, According to a New FDA Report - The Healthy @Reader's Digest
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - PR Newswire
Viatris Announces Launch of Breyna™ (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People With Asthma and Chronic Obstructive Pulmonary Disease, in Partnership With Kind - CSRwire
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Momentum Shift: Is Viatris Inc impacted by rising ratesWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating - Moomoo
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):